Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the ...
Hosted on MSN1mon
Ozempic-like jab 'fails' for millions with condition, study findsExperts had hoped a medication called exenatide, a weight loss jab in the same class of drugs as Ozempic and Wegovy, could help combat the degenerative nerve condition. But University College of ...
Medical Device Network on MSN1d
Vivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
Findings showed MDS-UPDRS OFF medication scores had worsened (increased) by 5.7 points in exenatide-treated patients compared with a 4.5 point increase with placebo. Treatment with once-weekly ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback